Kymera Therapeutics, Inc. 8-K

What Happened

• On June 25, 2026, Kymera Therapeutics announced (via an 8‑K and furnished press release) that it has completed enrollment in the global BROADEN2 Phase 2b trial of KT‑621, its first‑in‑class oral STAT6 degrader for moderate to severe atopic dermatitis (AD). Enrollment finished ahead of prior expectations, and Kymera now expects topline data by year‑end 2026, roughly six months earlier than its previous mid‑2027 guidance. The company also said it expects to initiate Phase 3 trials in AD by mid‑2027, subject to discussions with regulators.

Key Details

• Announcement date: June 25, 2026 (8‑K filing and press release furnished as Exhibit 99.1).
• Program: KT‑621, first‑in‑class oral STAT6 degrader for moderate to severe atopic dermatitis.
• Trial: BROADEN2 global Phase 2b — enrollment completed ahead of prior expectations.
• Timeline updates: topline data now expected by year‑end 2026 (previously mid‑2027); potential Phase 3 start by mid‑2027, pending regulator discussions.

Why It Matters

• Faster-than-expected enrollment advances Kymera’s clinical timeline: investors will get topline Phase 2b results sooner, which can materially affect near-term clinical and development decisions. The announcement also signals operational progress on KT‑621, the company’s lead AD candidate, and sets a clearer path toward potential Phase 3 initiation in 2027 (subject to regulatory interaction).